Nationwide clinical trials recruit thousands of participants to evaluate whether routine blood draws can catch malignancies before symptoms appear.
For decades, standard cancer screening has relied on single-organ tests like mammograms, colonoscopies, and Pap smears, leaving many of the deadliest malignancies without any routine early detection tools. Health systems across North America and research hubs nationwide are now evaluating whether a simple tube of blood can change that paradigm by screening for multiple cancers simultaneously.
Clinical Trial Milestones for Multi-Cancer Detection
The regulatory review process is moving forward. Clinical trials are evaluating the Galleri multi-cancer early detection blood test.
While tests like Galleri can be ordered under special designations, a thorough FDA approval process remains necessary before Medicare and commercial insurers cover them according to industry reporting.
“Today, the status quo in cancer screening is simply unacceptable. Many cancers are detected too late, after symptoms appear and the disease is too advanced for effective or curative-intent treatments. In fact, 70-80% of cancer deaths occur due to cancers we are not screening for at all.”
Josh Ofman, MD, MSHS, CEO at GRAIL, via Medindia
The Vanguard Study Expands Enrollment Across National Hubs
To establish broader clinical evidence, major research centers are actively enrolling participants in the National Cancer Institute-sponsored Vanguard Study.
The trial evaluates blood-based assays designed to detect signals from multiple cancers simultaneously.
“Currently we have evidence-based cancer screens for up to five different types of cancers. We have a lot of cancers that have high rates of death… no current screening test. It’s possible that these tests could pick that up.”
Dr. Mark Doescher, associate director for Community Outreach and Engagement at the Stephenson Cancer Center, via News9
Tracking Molecular Residual Disease and Cancer Relapse in Toronto
Beyond initial screening, liquid biopsies are being tested to monitor patients after primary treatment. In Toronto, a major Canadian observational study known as SHERLOCK plans to enroll 7,000 adults at the Princess Margaret Cancer Centre under the direction of Dr. Lillian Siu.
While a positive blood test does not guarantee a recurrence, it flags patients for closer monitoring or referral to separate interception trials. Researchers hope that repeated negative results could eventually allow doctors to safely reduce unnecessary chemotherapy or radiation, sparing patients from prolonged fatigue and nerve damage.
Translating Fragmentome and Methylation Patterns in the Lab
Behind these clinical trials is rapid technological refinement in how laboratories analyze cell-free DNA fragments shed into the bloodstream. Researchers at UCLA developed a method called MethylScan that examines DNA methylation, the chemical tags that control gene activity across different tissues. By targeting methylation rather than relying solely on genetic mutations, the approach reduces background noise and requires far less sequencing depth.
Similarly, scientists at the Johns Hopkins Kimmel Cancer Center validated an AI-powered blood test for liver cancer utilizing a platform called DELFI.
Early Detection Breakthroughs for High-Mortality Malignancies
Specific focus is directed toward cancers that typically present late without warning.
As large-scale trials mature, health systems face the ongoing task of proving that earlier detection translates into verifiable long-term survival benefits.
Keep reading
